News
Eppendorf Continues on Course for Success
May 02 2017
The Eppendorf Group successfully ended fiscal year 2016 with Group sales of €651.5 million (prior year: €629.1 million) and revenue growth of 3.6% (4.8% when adjusted for currency effects). Income from operations (EBIT) climbed 17.1% to €139.6 million (prior year: €119.3 million), amounting to an EBIT margin of 21.4% (prior year: 19.0%).
The Asian market and the services segment in particular contributed to this good result. During the reporting year, Eppendorf significantly increased expenses for research and development to €34.8 million (prior year: €31.9 million). In addition, the company expanded its global service and sales presence, among other things through the acquisition of a company in Ireland.
“Once again, we can look back on a good fiscal year. We want to continue developing dynamically and are currently working on a variety of measures to ensure we achieve profitable growth in the future as well,” said Thomas Bachmann, President & Chief Executive Officer of Eppendorf AG. “In addition to carrying out various internal projects, we took the step early this year, for instance, of acquiring a controlling interest in the Dutch company Bio-ITech B.V. after working closely with them last year on device and data networking.”
In 2017, the company will continue to focus on product and application development as well as on the ongoing expansion of its sales, development and production sites.
You will find the Eppendorf AG 2016 Annual Report at: corporate.eppendorf.com/en/company/annual-report/
Digital Edition
Lab Asia Dec 2025
December 2025
Chromatography Articles- Cutting-edge sample preparation tools help laboratories to stay ahead of the curveMass Spectrometry & Spectroscopy Articles- Unlocking the complexity of metabolomics: Pushi...
View all digital editions
Events
Jan 21 2026 Tokyo, Japan
Jan 28 2026 Tokyo, Japan
Jan 29 2026 New Delhi, India
Feb 07 2026 Boston, MA, USA
Asia Pharma Expo/Asia Lab Expo
Feb 12 2026 Dhaka, Bangladesh



